Frat2 mediates the oncogenic activation of Rac by MLL fusions

Blood

Volumn 120, Issue 24, 2012, Pages 4819-4828

  Walf Vorderwülbecke, Vanessa ^a   De Boer, Jasper ^a   Horton, Sarah J ^a   Van Amerongen, Renée ^b   Proost, Natalie ^b   Berns, Anton ^b   Williams, Owen ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISHEVELLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3; ONCOPROTEIN; PROTEIN FRAT2; RAC PROTEIN; RAC1 PROTEIN; RAC2 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL IMMORTALIZATION; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MIXED LINEAGE LEUKEMIA GENE; MOUSE; NONHUMAN; ONCOGENE; PRELEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84870729486     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-432534     Document Type: Article

References (58)

1. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674-2681.
2. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL rearranged acute myeloid leukemia. Leukemia. 2011;25(8):1239-1248.
3. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102(7):2395-2402. (Pubitemid 37193575)
4. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20(40):5695-5707. (Pubitemid 32928107)
5. Rodriguez-Perales S, Cano F, Lobato MN, Rabbitts TH. MLL gene fusions in human leukaemias: in vivo modelling to recapitulate these primary tumourigenic events. Int J Hematol. 2008;87(1):3-9.
6. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984-993.
7. Krivtsov AV, Feng Z, Armstrong SA. Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci. 2009;1176:144-149.
8. Somervaille TC, Cleary ML. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? Int J Hematol. 2010;91(5):735-741.
9. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316(5824):600-604. (Pubitemid 46683146)
10. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLLAF9 leukemia. Cancer Cell. 2008;13(6):483-495. (Pubitemid 351763903)
11. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18):2298-2307. (Pubitemid 37128644)
12. Zeisig BB, Milne T, Garcia-Cuellar MP, et al. Hoxa9 and Meis1 are key targets for MLL ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24(2):617-628. (Pubitemid 38057914)
13. Horton SJ, Grier DG, McGonigle GJ, et al. Continuous MLL ENL expression is necessary to establish a "Hox Code" and maintain immortalization of hematopoietic progenitor cells. Cancer Res. 2005;65(20):9245-9252. (Pubitemid 41507990)
14. Horton SJ, Walf-Vorderwulbecke V, Chatters SJ, Sebire NJ, de Boer J, Williams O. Acute myeloid leukemia induced by MLL ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities. Blood. 2009;113(20):4922-4929.
15. Zuber J, Rappaport AR, Luo W, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628-1640.
16. Yeung J, Esposito MT, Gandillet A, et al. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18(6):606-618.
17. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLLAF9 acute myeloid leukemia. Cancer Cell. 2006;10(4):257-268. (Pubitemid 44512188)
18. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
19. Muller LU, Schore RJ, Zheng Y, et al. Rac guanosine triphosphatases represent a potential target in AML. Leukemia. 2008;22(9):1803-1806.
20. Mizukawa B, Wei J, Shrestha M, et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLLAF9 leukemia. Blood. 2011;118(19):5235-5245.
21. van Amerongen R, Nawijn M, Franca-Koh J, et al. Frat is dispensable for canonical Wnt signaling in mammals. Genes Dev. 2005;19(4):425-430. (Pubitemid 40256273)
22. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005;102(37):13212-13217. (Pubitemid 41325003)
23. Li L, Yuan H, Weaver CD, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 1999;18(15):4233-4240. (Pubitemid 29364125)
24. Woodward MJ, de Boer J, Heidorn S, et al. Tnfaip8 is an essential gene for the regulation of glucocorticoid-mediated apoptosis of thymocytes. Cell Death Differ. 2010;17(2):316-323.
25. Fuerer C, Nusse R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One. 2010;5(2):e9370.
26. Hannon GJ, Sun P, Carnero A, et al. MaRX: an approach to genetics in mammalian cells. Science. 1999;283(5405):1129-1130.
27. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther. 2002;13(7):803-813. (Pubitemid 34493974)
28. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16(14):4226-4237. (Pubitemid 27298175)
29. Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes Dev. 2009;23(3):265-277.
30. Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci. 2005;8(1):34-42. (Pubitemid 41236729)
31. Habas R, Dawid IB, He X. Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev. 2003;17(2):295-309. (Pubitemid 36105900)
32. Jonkers J, Korswagen HC, Acton D, Breuer M, Berns A. Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J. 1997;16(3):441-450. (Pubitemid 27067774)
33. Saitoh T, Moriwaki J, Koike J, et al. Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun. 2001;281(3):815-820. (Pubitemid 32917875)
34. Hino S, Michiue T, Asashima M, Kikuchi A. Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of β-catenin. J Biol Chem. 2003;278(16):14066-14073. (Pubitemid 36799952)
35. van Amerongen R, Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene. 2010;29(1):93-104.
36. Kohlmann A, Schoch C, Dugas M, et al. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia. 2005;19(6):953-964. (Pubitemid 40862005)
37. Wang P, Lin C, Smith ER, et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol. 2009;29(22):6074-6085.
38. Chai JH, Locke DP, Ohta T, Greally JM, Nicholls RD. Retrotransposed genes such as Frat3 in the mouse chromosome 7C Prader-Willi syndrome region acquire the imprinted status of their insertion site. Mamm Genome. 2001;12(11):813-821. (Pubitemid 33022279)
39. Kobayashi S, Kohda T, Ichikawa H, et al. Paternal expression of a novel imprinted gene, Peg12/Frat3, in the mouse 7C region homologous to the Prader-Willi syndrome region. Biochem Biophys Res Commun. 2002;290(1):403-408. (Pubitemid 34694513)
40. Kobayashi T, Hino S, Oue N, et al. Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol. 2006;26(3):898-911. (Pubitemid 43146485)
41. Farooqui R, Zhu S, Fenteany G. Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. Exp Cell Res. 2006;312(9):1514-1525.
42. Upadhyay G, Goessling W, North TE, Xavier R, Zon LI, Yajnik V. Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling. Oncogene. 2008;27(44):5845-5855.
43. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894- 1907. (Pubitemid 44794525)
44. Zuber J, Radtke I, Pardee TS, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009;23(7):877-889.
45. Pervaiz S, Cao J, Chao OS, Chin YY, Clement MV. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene. 2001;20(43):6263-6268. (Pubitemid 32970414)
46. Zhang B, Zhang Y, Shacter E. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75. Mol Cell Biol. 2004;24(14):6205-6214. (Pubitemid 38891123)
47. Zhang B, Zhang Y, Dagher MC, Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005;65(14):6054-6062. (Pubitemid 40994389)
48. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101(20):7618-7623. (Pubitemid 38658078)
49. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008;455(7217):1205-1209.
50. Wang Z, Iwasaki M, Ficara F, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell. 2010;17(6):597-608.
51. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-480.
52. Stoothoff WH, Cho JH, McDonald RP, Johnson GV. FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation. J Biol Chem. 2005;280(1):270-276. (Pubitemid 40164989)
53. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-629. (Pubitemid 40868302)
54. Breitinger C, Maethner E, Garcia-Cuellar MP, et al. HOX genes regulate Rac1 activity in hematopoietic cells through control of Vav2 expression [published online ahead of print June 20, 2012]. Leukemia. doi:10.1038/leu.2012. 166.
55. Mack NA, Whalley HJ, Castillo-Lluva S, Malliri A. The diverse roles of Rac signaling in tumorigenesis. Cell Cycle. 2011;10(10):1571-1581.
56. Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One. 2011;6(2):e16951.
57. Cancelas JA, Williams DA. Rho GTPases in hematopoietic stem cell functions. Curr Opin Hematol. 2009;16(4):249-254.
58. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood. 2010;116(1):81-84.